Literature DB >> 8601101

Antibodies to streptokinase.

K Jennings.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8601101      PMCID： PMC2350089          DOI： 10.1136/bmj.312.7028.393

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking.

Authors:  J T Rivers; H D White; D B Cross; B F Williams; R M Norris
Journal:  J Am Coll Cardiol       Date:  1990-08       Impact factor: 24.094

2.  Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy.

Authors:  J M Elliott; D B Cross; S A Cederholm-Williams; H D White
Journal:  Am J Cardiol       Date:  1993-03-15       Impact factor: 2.778

3.  Anti-streptokinase antibodies inhibit fibrinolytic effects of anistreplase in acute myocardial infarction.

Authors:  J Brügemann; J van der Meer; V J Bom; W van der Schaaf; P A de Graeff; K I Lie
Journal:  Am J Cardiol       Date:  1993-08-15       Impact factor: 2.778

4.  Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction.

Authors:  R Fears; J Hearn; R Standring; J L Anderson; V J Marder
Journal:  Am Heart J       Date:  1992-08       Impact factor: 4.749

5.  Neutralising antibodies after streptokinase treatment for myocardial infarction: a persisting puzzle.

Authors:  K McGrath; C Hogan; D Hunt; C O'Malley; N Green; R Dauer; A Dalli
Journal:  Br Heart J       Date:  1995-08

6.  Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase.

Authors:  H S Lee; S Cross; R Davidson; T Reid; K Jennings
Journal:  Eur Heart J       Date:  1993-01       Impact factor: 29.983

7.  Hypersensitivity reactions to streptokinase in patients with high pre-treatment antistreptokinase antibody and neutralisation titres.

Authors:  H S Lee; S Yule; A McKenzie; S Cross; T Reid; R Davidson; K Jennings
Journal:  Eur Heart J       Date:  1993-12       Impact factor: 29.983
  7 in total
  5 in total

1.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 2.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

3.  The Streptokinase Therapy Complications and its Associated Risk Factors in Patients with Acute ST Elevation Myocardial Infarction.

Authors:  Naser Aslanabadi; Naser Safaie; Fereshteh Talebi; Samaneh Dousti; Taher Entezari-Maleki
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

4.  Effects of organic extracts of six Bangladeshi plants on in vitro thrombolysis and cytotoxicity.

Authors:  M Atiar Rahman; Rabeya Sultana; Talha Bin Emran; M Saiful Islam; M Ashiqur Rahman; Joti Sankhar Chakma; Harun-ur Rashid; Chowdhury Mohammad Monirul Hasan
Journal:  BMC Complement Altern Med       Date:  2013-01-30       Impact factor: 3.659

5.  Effect of Fagonia Arabica (Dhamasa) on in vitro thrombolysis.

Authors:  Sweta Prasad; Rajpal Singh Kashyap; Jayant Y Deopujari; Hemant J Purohit; Girdhar M Taori; Hatim F Daginawala
Journal:  BMC Complement Altern Med       Date:  2007-11-06       Impact factor: 3.659
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.